DURECT (NASDAQ:DRRX) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of DURECT (NASDAQ:DRRX) in a report issued on Friday morning. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.

Separately, HC Wainwright restated a “neutral” rating on shares of DURECT in a research note on Thursday, November 14th.

DURECT Stock Down 3.3 %

Shares of DURECT stock opened at $0.75 on Friday. DURECT has a twelve month low of $0.48 and a twelve month high of $1.88. The company has a market cap of $23.28 million, a price-to-earnings ratio of -1.23 and a beta of 1.01. The company’s 50 day moving average is $1.14 and its 200 day moving average is $1.34.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the business. International Assets Investment Management LLC increased its stake in shares of DURECT by 41.3% in the 2nd quarter. International Assets Investment Management LLC now owns 21,550 shares of the specialty pharmaceutical company’s stock worth $28,000 after purchasing an additional 6,300 shares in the last quarter. Accredited Investors Inc. bought a new stake in DURECT during the second quarter valued at about $113,000. Geode Capital Management LLC increased its position in DURECT by 4.8% in the third quarter. Geode Capital Management LLC now owns 319,905 shares of the specialty pharmaceutical company’s stock worth $429,000 after buying an additional 14,658 shares in the last quarter. Finally, Richmond Brothers Inc. raised its stake in shares of DURECT by 39.5% in the second quarter. Richmond Brothers Inc. now owns 1,072,014 shares of the specialty pharmaceutical company’s stock worth $1,383,000 after buying an additional 303,670 shares during the period. 28.03% of the stock is currently owned by institutional investors.

DURECT Company Profile

DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis.